Spotlight on Clinical Response
Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefford, Richard A. Scolyer and Georgina V. Long
James S. Wilmott
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
Varsha Tembe
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
Julie R. Howle
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
Raghwa Sharma
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
John F. Thompson
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
Helen Rizos
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
Roger S. Lo
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
Richard F. Kefford
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
Richard A. Scolyer
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
Georgina V. Long
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
DOI: 10.1158/1535-7163.MCT-12-0530 Published December 2012

Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 11, Issue 12, pp. 2704-2708
PubMed
Published By
Print ISSN
Online ISSN
History
- Received May 28, 2012
- Revision received August 26, 2012
- Accepted August 31, 2012
- Published first September 7, 2012.
Article Versions
- Previous version (September 7, 2012 - 12:57).
- Previous version (November 30, 2012 - 12:43).
- You are viewing the most recent version of this article.
Copyright & Usage
©2012 American Association for Cancer Research.
Author Information
- James S. Wilmott1,2,
- Varsha Tembe1,2,3,4,
- Julie R. Howle1,2,5,
- Raghwa Sharma5,
- John F. Thompson1,2,6,
- Helen Rizos1,2,3,4,
- Roger S. Lo7,8,9,
- Richard F. Kefford1,2,3,4,5,
- Richard A. Scolyer1,2,6, and
- Georgina V. Long1,2,3,4,5
- Authors' Affiliations: 1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
- Corresponding Author:
Georgina V. Long, Melanoma Institute Australia and Westmead Hospital, 40 Rocklands Road, North Sydney 2060, New South Wales, Australia. Phone: 61-2-9911-7200; Fax: 61-2-9954-9435; E-mail: georgina.long{at}sydney.edu.au
J. S. Wilmott and V. Tembe contributed equally to this work.
December 2012
Volume 11, Issue 12
Volume 11, Issue 12
Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefford, Richard A. Scolyer and Georgina V. Long
Mol Cancer Ther December 1 2012 (11) (12) 2704-2708; DOI: 10.1158/1535-7163.MCT-12-0530
Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefford, Richard A. Scolyer and Georgina V. Long
Mol Cancer Ther December 1 2012 (11) (12) 2704-2708; DOI: 10.1158/1535-7163.MCT-12-0530
Jump to section
Advertisement